Biognosys’ breakthrough mass spectrometric technology allows the simultaneous measurement of thousands of proteins in a single sample. The information is then stored in a digital map, which acts as a tool to monitor health, detects the onset of diseases, and discovers biomarkers. The goal is to use this technology to create truly personalised healthcare. The company was founded in 2008 and is located in Schlieren.
Now Biognosys was nominated for the STEP Award. The competition is designed to recognize innovative growth companies in Germany, Austria and Switzerland. The initiators, Infraserv Höchst and F.A.Z.-Institut Innovation Projects, are pursuing the same goal together with numerous sponsors and partners of the competition: giving companies an important boost in their growth phase. The STEP Award focuses on pharmaceutics, chemistry, life sciences, biotechnology, nanotechnology, medical engineering and greentech - businesses that are considered the sectors of the future.
The winner will receive a prize amounting to 100.000 Euro, consisting half in prize money, half in services supporting the company in an integral manner. Additional prizes will be awarded in the categories "market/client", "product/technology", "processes", "finances" and "sustainability".
Biognosys is invited for the Elevator Talk at the facilities of TÜV Hessen in Frankfurt am Main, October 29, 2012. The winner will be announced at the STEP Award-Gala, December 05, 2012.
0Comments
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines